GLP-1 Drugs May Protect Against Alzheimer’s
University of Florida A study led by researchers in the University of Florida College of Pharmacy has found that a pair of popular glucose-lowering medications may have protective effects…
University of Florida A study led by researchers in the University of Florida College of Pharmacy has found that a pair of popular glucose-lowering medications may have protective effects…
submitted by /u/Diamond-Is-Not-Crash [link] [comments]
Pfizer announced it is ending its development of its experimental oral GLP-1 drug to treat obesity, the company said on Monday, after a patient in a trial suffered a liver injury potentially caused by the experimental drug known as danuglipron.
Pfizer Halts Obesity Pill Tests Amid Safety Concerns Newser Pfizer ends development of potential pill obesity treatment CNN NVO, LLY, GPCR & VKTX Stocks Gain Following PFE’s Obesity Study Setback Yahoo Finance Pfizer Halts Obesity-Drug Development. What It Means for Eli Lilly, Novo Nordisk. Barron’s Pfizer scraps daily weight loss pill after liver injury in one patient CNBC
Hi I have terrible written expression skills, but I am good at math. So bear with me through this post and youll be rewarded. Hims & Hers Market Cap: $6.5B Q1 2025 Guidance: HIMS is projecting to grow Revenues at 87% – 94% YoY. This is in the range of $520 million to $540 million. … Read more
Smaller, more easily made drugs that target GLP-1 could treat obesity and diabetes with fewer side effects
A HEALTHCARE worker has insisted Mounjaro has been “life-changing” after she shed five stone in seven months. Connie Bulloch, from Cambuslang, near Glasgow, started using the weight loss jabs in June last year. Connie Bulloch weighed 15st 9lb at her heaviestConnie Bulloch Connie BullochThe healthcare worker is now 10st 7lb[/caption] GettyConnie hails Mounjaro as ‘life-changing’[/caption] … Read more
Are your patients wasting away? Dr Tamaan Osbourne-Roberts explains why lifestyle interventions are a key supplement to GLP-1 agonists for weight management. Medscape
Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, have recently gained attention for their effectiveness in managing weight gain, high blood sugar, and even reducing alcohol cravings. A new clinical … Read more